No products in the cart.
Treatment with semaglutide in patients with obesity may be associated with weight loss
1. In this study, treatment with semaglutide at any of the 5 doses approved for long-term weight management led to ...
Tag: glucagon-like peptide-1 (GLP-1) receptor agonists
Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk
1. From baseline to 52 weeks, tirzepatide resulted in a greater reduction in mean HbA1c levels compared to insulin glargine. ...
Once weekly tirzepatide is superior to daily insulin degludec for treatment of uncontrolled type 2 diabetes
1. Patients receiving tirzepatide (5, 10, or 15 mg) reported significantly greater reductions in HbA1c compared to daily insulin degludec ...
Tirzepatide improves glycemic control and weight loss in patients with type 2 diabetes
1. Tirzepatide was superior to placebo with regard to changes in HbA1c, serum glucose, body weight loss, and proportion of ...
Combined cagrilintide and semaglutide for weight management well-tolerated in early clinical trials
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to ...
The PIONEER 6 trial: semaglutide in type 2 diabetic patients does not increase cardiovascular risk
1. Over a median period of almost 16 months, type 2 diabetic (T2DM) patients randomized to oral semaglutide for experienced ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.